Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bonestiff is a pharmaceutical formulation marketed by Emblazon Life Sciences, an Indian pharmaceutical company. The primary active ingredient in Bonestiff is typically *Cissus quadrangularis* extract, a medicinal plant widely recognized for its osteogenic properties. It is primarily indicated for accelerating the healing of bone fractures, managing osteoporosis, and supporting overall bone health. The mechanism of action involves the stimulation of osteoblast proliferation and differentiation, which enhances the mineralization process and the uptake of essential minerals such as calcium and phosphorus into the bone matrix. Additionally, it may exhibit analgesic and anti-inflammatory effects, making it useful in the management of joint pain and orthopedic injuries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bonestiff.